These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 29305768)

  • 1. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents.
    Saxon DR; Rasouli N; Eckel RH
    Drugs; 2018 Feb; 78(2):203-214. PubMed ID: 29305768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies.
    Zoungas S; Patel A
    Ann N Y Acad Sci; 2010 Nov; 1212():29-40. PubMed ID: 21091713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention of cardiovascular disease in type 2 diabetic patients].
    Yokota C
    Nihon Rinsho; 2003 Jul; 61(7):1161-6. PubMed ID: 12877078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is type-2 diabetes mellitus preventable?].
    Jermendy G
    Orv Hetil; 2003 Sep; 144(39):1909-17. PubMed ID: 14598569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 6. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
    Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
    Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the look AHEAD study intervention on medication use and related cost to treat cardiovascular disease risk factors in individuals with type 2 diabetes.
    Redmon JB; Bertoni AG; Connelly S; Feeney PA; Glasser SP; Glick H; Greenway F; Hesson LA; Lawlor MS; Montez M; Montgomery B;
    Diabetes Care; 2010 Jun; 33(6):1153-8. PubMed ID: 20332353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of type 2 diabetes mellitus to reduce cardiovascular morbidity and mortality: a review of the evidence.
    Giles TD
    J Clin Hypertens (Greenwich); 2009 Sep; 11(9):512-9. PubMed ID: 19751467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A search for novel pathways of effective prevention of cardiovascular complications in patients with type 2 diabetes mellitus: advance trial].
    Karpov IuA; Shubina AT
    Kardiologiia; 2007; 47(10):90-5. PubMed ID: 18260953
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update.
    Hovens MM; Tamsma JT; Beishuizen ED; Huisman MV
    Drugs; 2005; 65(4):433-45. PubMed ID: 15733008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of orlistat initiation on cardiovascular treatment use: a 6-year population-based cohort study.
    Czernichow S; Knol MJ; Fezeu L; Grobbee DE
    Eur J Prev Cardiol; 2012 Jun; 19(3):484-9. PubMed ID: 21464100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging pharmacologic therapies for type 2 diabetes, dyslipidemia, and obesity.
    Taylor JR; Dietrich E; Powell JG
    Clin Ther; 2013 Jan; 35(1):A3-17. PubMed ID: 23328274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing cardiovascular disease risk in patients with diabetes: a message from the National Diabetes Education Program.
    Blonde L; Dempster J; Gallivan JM; Warren-Boulton E
    J Am Acad Nurse Pract; 2006 Nov; 18(11):524-33. PubMed ID: 17064330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-Related Differences in the Control of Cardiovascular Risk Factors in Primary Care for Elderly Patients With Type 2 Diabetes: A Cohort Study.
    Al-Salameh A; Bucher S; Bauduceau B; Benattar-Zibi L; Berrut G; Bertin P; Corruble E; Danchin N; Derumeaux G; Doucet J; Falissard B; Forette F; Hanon O; Ourabah R; Pasquier F; Pinget M; Ringa V; Becquemont L
    Can J Diabetes; 2018 Aug; 42(4):365-371.e2. PubMed ID: 29037572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.
    Otsuki M; Goya K; Kasayama S
    Vasc Health Risk Manag; 2005; 1(3):209-15. PubMed ID: 17319106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
    Naruszewicz M
    Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].
    Ruiz J
    Rev Med Suisse; 2006 Jan; 2(48):116-8. PubMed ID: 16463795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phytochemical, Anti-diabetic and Cardiovascular Properties of Urtica dioica L. (Urticaceae): A Review.
    El Haouari M; Rosado JA
    Mini Rev Med Chem; 2019; 19(1):63-71. PubMed ID: 30246639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of non-insulin-based glucose-lowering therapies on cardiovascular outcomes in patients with type 2 diabetes.
    Wiernek SL; Cavender MA
    J Fam Pract; 2017 Jun; 66(6 Suppl):. PubMed ID: 28700767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whence and whither the fixed-dose combination?
    Bailey CJ
    Diab Vasc Dis Res; 2005 May; 2(2):51-3. PubMed ID: 16305058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.